Equities research analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings of ($1.22) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from ($1.36) to ($1.03). Alnylam Pharmaceuticals posted earnings per share of ($1.05) during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.2%. The business is expected to announce its next quarterly earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($5.31) per share for the current financial year, with EPS estimates ranging from ($6.43) to ($4.74). For the next year, analysts expect that the business will report earnings of ($4.86) per share, with EPS estimates ranging from ($6.17) to ($3.10). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The business’s revenue for the quarter was up 160.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.21) EPS.

Several equities analysts have recently weighed in on ALNY shares. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a research note on Monday, May 15th. Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. Chardan Capital reduced their target price on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, May 15th. FBR & Co reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, March 20th. Finally, Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $71.29.

Alnylam Pharmaceuticals (ALNY) traded up 6.49% during mid-day trading on Monday, reaching $81.01. 562,856 shares of the company’s stock were exchanged. The stock’s market cap is $6.98 billion. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $82.31. The company has a 50-day moving average of $66.00 and a 200-day moving average of $50.99.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/06/19/zacks-analysts-expect-alnylam-pharmaceuticals-inc-alny-to-post-1-22-earnings-per-share.html.

In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares in the company, valued at $393,750. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the sale, the senior vice president now owns 43,047 shares of the company’s stock, valued at $2,798,055. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in ALNY. FMR LLC raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 12,907,883 shares of the biopharmaceutical company’s stock valued at $661,530,000 after buying an additional 35,803 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after buying an additional 31,208 shares during the last quarter. Dodge & Cox bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $344,633,000. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock valued at $290,086,000 after buying an additional 200,890 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Institutional investors and hedge funds own 90.04% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.